Assessing blood platelets as RNA biomarker source for prostate cancer

Biomarkers. 2016 Nov;21(7):653-9. doi: 10.3109/1354750X.2016.1171909. Epub 2016 Apr 28.

Abstract

Context: Blood platelets may offer as RNA biomarker source for cancer as recently described for an oncogenic transcript in glioma patients and for PCA3 in prostate cancer (PCa) patients.

Objective: Here, we elaborated on this aspect for PCa.

Materials and methods: PCA3 and other PCa-associated RNA markers were measured in platelets of PCa patients (cases) and healthy subjects (controls) in comparison to PCa cell lines by relative quantitative RT-PCR.

Results: The RNA markers displayed heterogeneous expression patterns in cell lines and platelets, however, without significant differences between cases and controls.

Discussion and conclusion: The data do not support platelets as a profitable RNA source for early detection of PCa. Nonetheless, certain PCa-derived RNA markers in platelets may merit further investigation as potential prognostic biomarkers for PCa.

Keywords: Biomaterial; PCA3; thrombocyte.

Publication types

  • Observational Study

MeSH terms

  • Antigens, Neoplasm / analysis
  • Biomarkers, Tumor / analysis*
  • Blood Platelets*
  • Case-Control Studies
  • Humans
  • Male
  • Prostatic Neoplasms / diagnosis*
  • RNA*
  • Tumor Cells, Cultured

Substances

  • Antigens, Neoplasm
  • Biomarkers, Tumor
  • prostate cancer antigen 3, human
  • RNA